Relapsed Peripheral T-Cell Lymphoma

Explore clinical trials studying Relapsed Peripheral T-Cell Lymphoma. Study availability and eligibility vary by location and protocol.

7 public trials 3 recruiting studies

Refine in advanced search Browse all conditions

Relapsed Peripheral T-Cell Lymphoma trial results

Recruiting

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

NCT06508463

Conditions: Anaplastic Large Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +17 more
Locations: Mayo Clinic in Arizona Scottsdale, Arizona, United States

Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Recruiting

Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma

NCT06160843

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations: National Cancer Centre, Singapore Singapore

View Trial Details

Recruiting

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

NCT06151106

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations: The First Affiliated Hosptial of Xiamen University Xiamen, Fujian, China

View Trial Details

Not Yet Recruiting

Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma

NCT06671717

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations: Peking University, Institute of Hematolgoy, Beijing, Beijing, China

View Trial Details

Completed

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

NCT03496779

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations: ZNA Stuivenberg Antwerp, Belgium

A. Z. Sint-Jan Bruges, Belgium

Clinique Universitaire Saint LUC Brussels, Belgium

Institut Jules Bordet Brussels, Belgium

View all 39 locations

View Trial Details

Completed

Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies

NCT02106650

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations: City of Hope Duarte, California, United States

Cancer Center of Kansas Wichita, Kansas, United States

Seattle Cancer Care Alliance Seattle, Washington, United States

View Trial Details

Completed

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

NCT01482962

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations: Birmingham, Alabama, United States

La Jolla, California, United States

Orlando, Florida, United States

Tampa, Florida, United States

View all 151 locations

View Trial Details

Relapsed Peripheral T-Cell Lymphoma

Relapsed Peripheral T-Cell Lymphoma trial results

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Related conditions